Table 1.
Baseline characteristics of the study population at CAISM/UNICAMP from 2000 to 2015
| Characteristics | Median (%) |
|---|---|
| Age (years) | 28 (13–46) |
| Parity | 1 (0–9) |
| Schooling years (n = 769) | |
| < 8 | 60.9 |
| 8–11 yrs. | 32.2 |
| > 12 | 5.1 |
| No schooling | 1.8 |
| Ethnicity: White | 61.2 |
| HIV diagnosis (n = 789) | |
| Prior to pregnancy | 62.5 |
| During pregnancy | 37.5 |
| In use of ART at conception (n = 787) | 27.6 |
| In use of Efavirenz at conception (n = 793) | 10.2 |
| Planned pregnancy (n = 382) | 25.7 |
| Heterosexual transmission (n = 408) | 93.1 |
| Baseline CD4 median (cells/mm3) | 444 (3–1915) |
| Peripartum CD4 median (cells/mm3) | 552 (5–2164) |
| Median time of ART use (days) | 152.5 (4–292) |
| Median of detectable peripartum viral load (copies/ml) | 815 (43–500.000) |
| Peripartum Viral Load < 50 (copies/ml) (n = 732) | 58.9 |
| CDC classification (n = 758) | |
| 1 | 29.9 |
| 2 | 51.6 |
| 3 | 18.5 |
| Substance abuse (n = 568) | 14.3 |
| Alcoholism (n = 528) | 5.7 |
| Smoking (n = 538) | 14.1 |
| ART adherence during prenatal care | 84.3 |
| Changed ART (n = 776) | 19.2 |
| Intravenous AZT (n = 775) | 94.8 |
| Antiretroviral regimens during pregnancy (n = 793) | |
| None | 1.9 |
| AZT monotherapy | 2.9 |
| Dual therapy | 1.4 |
| 2 NRTI + 1 NNRTI | 17.9 |
| AZT + 3TC + NVP | 16.8 |
| TDF + 3TC + NVP | 0.1 |
| d4T + 3TC + NVP | 0.5 |
| AZT + 3TC + EFV | 0.3 |
| TDF + 3TC + EFV | 0.3 |
| 2 NRTI + 1 PI | 74.9 |
| AZT + 3TC + LPV/r | 48.5 |
| TDF + 3TC + LPV/r | 3.4 |
| d4T + 3TC + LPV/r | 0.1 |
| TDF + AZT + 3TC + LPV/r | 1.5 |
| AZT + 3TC + ATV/r | 1.8 |
| TDF + 3TC + ATV/r | 1.0 |
| ABC + 3TC + ATV/r | 0.1 |
| TDF + AZT + 3TC + ATV/r | 0.3 |
| AZT + 3TC + NFV | 16.8 |
| d4T + 3TC + NFV | 0.1 |
| 2 NRTI + Other PI* | 1.3 |
| 2 NRTI + PI** + RAL | 0.9 |
| 2 NRTI + NNRTI + PI | 0.6 |
| Total | 100 |
ART antiretroviral therapy, NRTI nucleos(t)ide reverse transcriptase inhibitors, AZT zidovudine, 3TC lamivudine, TDF tenofovir, d4T stavudine, ABC abacavir, NNRTI non-nucleoside reverse transcriptase inhibitor NVP nevirapine, EFV efavirenz, PI protease inhibitor, NFV nelfinavir, LPV lopinavir, r ritonavir, ATV atazanavir, IDV indinavir, FPV fosamprenavir, SQV saquinavir, RAL raltegravir, CDC Centers for Disease Control and Prevention
Other PI* IDV/r (6), FPV/r (2), SQV (2)
PI** DRV/r (3), LPV/r (4) included in LPV/r group